Telix Competitors

TLX Stock   15.76  0.16  1.03%   
Telix Pharmaceuticals competes with HUTCHMED DRC, Vestis, Xponential Fitness, HE Equipment, and Air Lease; as well as few others. The company runs under Healthcare sector within Biotechnology industry. Analyzing Telix Pharmaceuticals competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Telix Pharmaceuticals to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Telix Pharmaceuticals Correlation with its peers.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Telix Pharmaceuticals competition on your existing holdings.
  
Return On Tangible Assets is likely to rise to 0.02 in 2024. Return On Capital Employed is likely to rise to 0.07 in 2024. At this time, Telix Pharmaceuticals' Other Current Assets are fairly stable compared to the past year. Return On Tangible Assets is likely to rise to 0.02 in 2024, whereas Total Assets are likely to drop slightly above 253.4 M in 2024.
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
13.3415.7518.16
Details
Intrinsic
Valuation
LowRealHigh
14.1819.0221.43
Details
Naive
Forecast
LowNextHigh
11.5613.9716.37
Details
1 Analysts
Consensus
LowTargetHigh
29.5832.5036.08
Details

Telix Pharmaceuticals Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Telix Pharmaceuticals and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Telix and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Telix Pharmaceuticals does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
ALXPOF
ALHEES
HEESXPOF
ALVOHCM
ALVSTS
XPOFVSTS
  
High negative correlations   
ALVOVSTS
XPOFHCM
ALHCM
VSTSHCM
ALVOXPOF
ALVOAL

Risk-Adjusted Indicators

There is a big difference between Telix Stock performing well and Telix Pharmaceuticals Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Telix Pharmaceuticals' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.

Cross Equities Net Income Analysis

Compare Telix Pharmaceuticals and related stocks such as Omni Health, HUTCHMED DRC, and Vestis Net Income Over Time
Select Fundamental
Price To Sales RatioPtb Ratio
Days Sales OutstandingBook Value Per Share
Free Cash Flow YieldInvested Capital
Operating Cash Flow Per ShareAverage Payables
Stock Based Compensation To RevenueCapex To Depreciation
Pb RatioEv To Sales
Free Cash Flow Per ShareRoic
Inventory TurnoverNet Income Per Share
Days Of Inventory On HandPayables Turnover
Sales General And Administrative To RevenueAverage Inventory
Research And Ddevelopement To RevenueCapex To Revenue
Cash Per SharePocfratio
Interest CoveragePayout Ratio
Capex To Operating Cash FlowPfcf Ratio
Days Payables OutstandingNet Current Asset Value
Income QualityRoe
Tangible Asset ValueEv To Operating Cash Flow
Pe RatioReturn On Tangible Assets
Ev To Free Cash FlowIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Graham NumberShareholders Equity Per Share
Debt To EquityCapex Per Share
Graham Net NetAverage Receivables
Revenue Per ShareInterest Debt Per Share
Debt To AssetsEnterprise Value Over E B I T D A
Dividend YieldEarnings Yield
Short Term Coverage RatiosPrice Earnings Ratio
Operating CyclePrice Book Value Ratio
Price Earnings To Growth RatioDays Of Payables Outstanding
Dividend Payout RatioPrice To Operating Cash Flows Ratio
Price To Free Cash Flows RatioPretax Profit Margin
Ebt Per EbitOperating Profit Margin
Effective Tax RateCompany Equity Multiplier
Long Term Debt To CapitalizationTotal Debt To Capitalization
Return On Capital EmployedDebt Equity Ratio
Ebit Per RevenueQuick Ratio
Dividend Paid And Capex Coverage RatioNet Income Per E B T
Cash RatioCash Conversion Cycle
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Fixed Asset TurnoverCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On Equity
201020112012201320142015201620172018201920202021202220232024
OMHE(33.7 K)(33.7 K)(33.7 K)(33.7 K)(33.7 K)(534 K)1.3 M1.3 M1.3 M1.3 M1.3 M1.3 M1.3 M1.5 M1.5 M
HCM(6.8 M)710.2 K3.6 M5.9 M5.4 MM11.7 M(26.7 M)(74.8 M)(144.4 M)(194.6 M)(227.7 M)(410.1 M)100.8 M105.8 M
VSTS111.6 M111.6 M111.6 M111.6 M111.6 M111.6 M111.6 M111.6 M111.6 M111.6 M74.3 M141.7 M213.2 M21 M19.9 M
XPOF(42.5 M)(42.5 M)(42.5 M)(42.5 M)(42.5 M)(42.5 M)(42.5 M)(42.5 M)(42.5 M)(37.1 M)(13.6 M)(51.4 M)2.9 M(17.5 M)(18.4 M)
HEES3.3 M8.9 M28.8 M44.1 M55.1 M44.3 M37.2 M109.7 M76.6 M87.2 M(32.7 M)60.6 M132.2 M169.3 M177.8 M
AL53.2 M53.2 M131.9 M190.4 M256 M253.4 M374.9 M756.2 M510.8 M587.1 M516.3 M436.6 M(97 M)614.6 M387.9 M
ALVO(209.9 M)(209.9 M)(209.9 M)(209.9 M)(209.9 M)(209.9 M)(209.9 M)(209.9 M)(209.9 M)(209.9 M)(170 M)(101.5 M)(513.6 M)(551.7 M)(524.1 M)

Telix Pharmaceuticals and related stocks such as Omni Health, HUTCHMED DRC, and Vestis Net Income description

Net income is one of the most important fundamental items in finance. It plays a large role in Telix Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Telix Pharmaceuticals Limited operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.

Telix Pharmaceuticals Competitive Analysis

The better you understand Telix Pharmaceuticals competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Telix Pharmaceuticals' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Telix Pharmaceuticals' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
TLX HCM VSTS XPOF HEES AL ALVO
 1.03 
 15.76 
Telix
 1.83 
 15.58 
HUTCHMED
 1.83 
 16.05 
Vestis
 7.69 
 15.13 
Xponential
 0.25 
 55.89 
HEES
 0.10 
 49.42 
Air
 1.20 
 11.80 
Alvotech
Market Volatility
(90 Days Market Risk)
Market Performance
(90 Days Performance)
Odds of Financial Distress
(Probability Of Bankruptcy)
Current Valuation
(Equity Enterprise Value)
Buy or Sell Advice
(Average Analysts Consensus)
Trade Advice
(90 Days Macroaxis Advice)
Current Ratio
Net Asset
Profit Margin
EBITDA
Operating Margin
Current Valuation
Price To Book
Retained Earnings
Current Asset
Five Year Return
Beta
Number Of Employees
Shares Outstanding
Cash Flow From Operations
Annual Yield
Total Debt
Return On Equity
Return On Asset
Number Of Shares Shorted
Book Value Per Share
Current Liabilities
Total Asset
Short Ratio
Target Price
Debt To Equity
Last Dividend Paid
Shares Owned By Institutions
Market Capitalization
Price To Earning
Price To Earnings To Growth
Price To Sales
Net Income
Earnings Per Share
Shares Owned By Insiders
Revenue
Working Capital
Cash And Equivalents
Cash Per Share
Gross Profit
Day Typical Price
Accumulation Distribution
Market Facilitation Index
Daily Balance Of Power
Period Momentum Indicator
Rate Of Daily Change
Day Median Price
Price Action Indicator
Relative Strength Index
Coefficient Of Variation
Mean Deviation
Jensen Alpha
Total Risk Alpha
Sortino Ratio
Downside Variance
Standard Deviation
Kurtosis
Potential Upside
Treynor Ratio
Maximum Drawdown
Variance
Market Risk Adjusted Performance
Risk Adjusted Performance
Skewness
Semi Deviation
Information Ratio
Value At Risk
Expected Short fall
Downside Deviation
Semi Variance

Telix Pharmaceuticals Competition Performance Charts

Five steps to successful analysis of Telix Pharmaceuticals Competition

Telix Pharmaceuticals' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Telix Pharmaceuticals in relation to its competition. Telix Pharmaceuticals' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Telix Pharmaceuticals in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Telix Pharmaceuticals' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Telix Pharmaceuticals, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Telix Pharmaceuticals position

In addition to having Telix Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Broad Sovereign ETFs Thematic Idea Now

Broad Sovereign ETFs
Broad Sovereign ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Broad Sovereign ETFs theme has 14 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Broad Sovereign ETFs Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Telix Stock Analysis

When running Telix Pharmaceuticals' price analysis, check to measure Telix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Telix Pharmaceuticals is operating at the current time. Most of Telix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Telix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Telix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Telix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.